What is Epitalon?
Epitalon is a four amino acid synthetic peptide developed in St. Petersburg as a defined version of Epithalamin, an extract of the pineal gland (a small hormone gland in the brain). In cultured human cells it activates telomerase, the enzyme that rebuilds telomeres (the protective caps on chromosome ends), and lengthens telomeres, and in mice it modestly extended life span and reduced spontaneous tumors, but those effects have not been measured in people. Two Russian human studies reported higher melatonin output after the peptide; their abstracts do not state the design, the sample size, or whether participants were randomized (assigned by chance), and both come from the network that developed it. The randomized trial often cited for epitalon tested the pineal extract Epithalamin, not the synthetic peptide. It was on the 503A Category 2 list (compounding ingredients flagged for significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn. At the July 2026 Pharmacy Compounding Advisory Committee meeting on adding it to the 503A bulks list (ingredients pharmacies may use to compound drugs for individual patients), FDA's drug center recommended against listing and the committee voted in favor, according to HHS. On October 28, 2026 HHS released a draft enforcement discretion policy: HHS says it does not intend to take enforcement action against licensed pharmacies and physicians that compound single-ingredient epitalon by injection under the skin or into muscle, in intermittent courses on a patient-specific prescription, under strict quality and reporting conditions. The draft policy is not an FDA approval, does not add epitalon to the bulks list, and does not change its evidence grade.
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on the bovine pineal extract Epithalamin. It is also known as Epithalon, Epithalone, Ala-Glu-Asp-Gly, AEDG peptide, Epithalamin (pineal extract it was derived from), Epitalon peptide, Epithalon peptide, Epitalone.
How does it work?
In human fibroblast and other cell lines, epitalon induces expression of the telomerase catalytic subunit (hTERT), increases telomerase activity, and lengthens telomeres; a 2025 study found telomere elongation through telomerase upregulation or the alternative lengthening pathway depending on the cell line. The developers also propose that it binds DNA and regulates gene expression epigenetically and that it normalizes melatonin rhythms through the pineal gland. These mechanisms are documented in cell culture and rodents; in people, only the melatonin effect has been reported, in two studies whose abstracts do not state their design.
| Cluster | Longevity and mitochondrial |
|---|---|
| Routes | Subcutaneous injection (as sold); Intramuscular injection (Russian Epithalamin reports); Intranasal and oral products exist without absorption data |
| Conditions studied | Skin aging and cosmetic repair; Sleep disorders; Longevity and healthy aging |
| Record | v4, reviewed, verified Nov 1, 2026 |
Epitalon benefits: what the evidence shows
Two indexed human studies decide the grade. Korkushko 2007 (PMID 17969590) reported that the pineal extract Epithalamin and synthetic Epitalon both raised night melatonin in elderly people with pineal insufficiency, and a 2020 study (PMID 33280326) reported that AEDG peptide raised urinary 6-sulfatoxymelatonin 1.7-fold in middle-aged people and changed clock gene expression in blood cells. Neither abstract states the design, the sample size, or whether participants were randomized, so they count as human studies of unconfirmed design, not as a randomized trial. The randomized, placebo controlled trial often cited for epitalon (PMID 14523363) tested the bovine pineal extract Epithalamin, a different preparation from synthetic epitalon, so it does not raise the grade; telomere lengthening has been shown only in cultured human cells and life span effects only in mice.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 1 | 266 |
| Human observational studies | 2 | n/a |
| Animal studies | 3 | n/a |
| All indexed studies | 6 | 266 |
Human evidence
Korkushko 2007 (Russian): in elderly people, both Epithalamin and synthetic Epitalon raised the night melatonin level in those with pineal gland functional insufficiency; the authors report no side effects. Ivko 2020 (Russian): AEDG peptide raised urinary 6-sulfatoxymelatonin excretion 1.7-fold in middle-aged people and shifted expression of the clock genes Clock, Csnk1e, and Cry2 in blood cells of people with reduced melatonin production. Neither abstract states the study design, the sample size, or whether participants were randomized, and both come from the network that developed the peptide. Khavinson and Morozov (2003) is described in its full text as randomized and placebo controlled and reported lower mortality in elderly people followed for 6 to 8 years, but it tested the pineal extract Epithalamin (with Thymalin), not synthetic epitalon, so it does not count toward epitalon's grade. No human study has measured telomere length or life span after epitalon. Cell studies used human fibroblasts and other human cell lines, not people.
Animal evidence
Anisimov et al. (2003) gave female Swiss-derived SHR mice epitalon 0.1 ug subcutaneously five times a week, monthly courses, from age 3 months until death: the peptide slowed some aging biomarkers, increased the life span of the longest lived 10% of mice, and reduced spontaneous tumor incidence, but did not significantly change mean life span. Rat studies from the same group report protective effects against light-induced pineal aging and retinal changes.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells2003 PMID 12937682 | In vitro study of human fetal fibroblast culturesHuman somatic cell cultures | Epitalon induced telomerase catalytic subunit expression, increased telomerase activity, and lengthened telomeres in cultured cells | Evidence: Animal-only evidence |
| Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice2003 PMID 14501183 | Lifelong controlled mouse study, monthly subcutaneous courses from 3 months of ageFemale Swiss-derived SHR mice | Slowed several aging biomarkers, increased life span of the last 10% of survivors, and reduced spontaneous tumor incidence; mean life span not significantly changed | Evidence: Animal-only evidence |
| Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people2007 PMID 17969590 | Study in monkeys and people; design, randomization, and blinding not stated in the abstract; Russian languageOld monkeys and elderly people, including people with pineal gland functional insufficiency; sample size not stated in the abstract | Epithalamin and synthetic Epitalon restored night melatonin release and the circadian melatonin rhythm; elderly people with pineal insufficiency had higher night melatonin; authors report no side effects | Evidence: Human observational evidence |
| AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging2020 PMID 33280326 | Human study; design, randomization, and blinding not stated in the abstract; Russian languageMiddle-aged people, including people with reduced melatonin production; sample size not stated in the abstract | AEDG peptide raised urinary 6-sulfatoxymelatonin excretion 1.7-fold and shifted expression of the clock genes Clock, Csnk1e, and Cry2 in blood cells | Evidence: Human observational evidence |
| Peptides of pineal gland and thymus prolong human life2003 PMID 14523363 | Randomized, placebo controlled trial of the pineal extract Epithalamin and the thymus extract Thymalin (PubMed publication type: randomized controlled trial; the full text describes stratified randomization into 3 groups); did not test synthetic epitalonn = 266 Elderly people in St. Petersburg and Kiev: the abstract reports 266 people followed for 6 to 8 years; the full text describes 152 people randomized to placebo (48), Thymalin (58), or Epithalamin (46), plus a second arm of 94 women | Eight-year mortality 13.6% with placebo, 6.6% with Thymalin, and 8.5% with Epithalamin; from the developing institute and never independently replicated; tested the extract Epithalamin, not synthetic epitalon, so it does not raise epitalon's grade | Evidence: Human RCT evidence |
| Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity2025 PMID 40908429 | In vitro study of multiple human cell linesHuman cell lines | Telomere elongation via telomerase upregulation in some lines and alternative lengthening of telomeres in others | Evidence: Animal-only evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Skin aging and cosmetic repair | Evidence: Animal-only evidence | Marketed for skin and longevity; its two indexed human studies measured melatonin, not skin, and their abstracts do not state design or sample size; telomere lengthening has been shown only in cultured human cells. |
| Sleep disorders | Evidence: Human observational evidence | Marketed for melatonin and circadian effects; two Russian human studies reported higher melatonin output, but their abstracts do not state design or sample size, and both measured melatonin, not sleep. |
| Longevity and healthy aging | Evidence: Animal-only evidence | Telomere lengthening has been shown only in cultured human cells, and no human study has measured telomere length or life span after epitalon; two Russian human studies measured melatonin, with design and sample size not stated in their abstracts; the randomized trial often cited tested the pineal extract Epithalamin, not synthetic epitalon, so it does not raise the grade; FDA's drug center recommended against 503A listing and the advisory committee voted in favor (HHS policy, Appendix B); HHS's October 2026 draft policy, which is not an approval, covers conditional compounding of the single-ingredient product. |
Is Epitalon legal in the United States?
FDA and compounding status
Epitalon is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 24, 2026 for insomnia: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds epitalon when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous or intramuscular injection, in intermittent courses), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add epitalon to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.
WADA status
WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.
Regulatory timeline
- HHS
HHS draft policy lets licensed pharmacies compound six peptides without enforcement action
HHS Secretary Robert F. Kennedy Jr. announced a draft enforcement discretion policy (FR Doc. 2026-22192, filed October 28 and published in the Federal Register on October 30, 2026). HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157, epitalon, KPV, MOTS-c, semax, or TB-500, if the product contains a single active ingredient, uses an allowed route, is made from an FDA-registered manufacturer's substance with a tested certificate of analysis, carries a patient-specific prescription, and serious adverse events are reported to FDA. It is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Comments are open through November 13, 2026 on Docket HHS-OASH-2026-0496.
- PCAC
FDA advisory committee reviews six peptides; FDA's briefing recommends against listing
At its July 23 to 24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon for the 503A bulks list. FDA's own briefing slides proposed not adding any of them. The committee voted in favor of listing all six, as HHS confirmed in its October 2026 peptide policy. The committee is advisory, and FDA proposed no rule, so none of the six was added to the 503A bulks list.
Regulatory: Nomination withdrawnSource: FDA: Pharmacy Compounding Advisory Committee, July 23, 2026, FDA presentation slides - FDA
FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2
FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.
- FDA
FDA places a batch of nominated peptides in 503A Category 2
In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.
Full tracker for Epitalon or the category-wide tracker.
Email me when Epitalon's status changes
Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.
What published studies of Epitalon used
Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.
Not established in human literature. Mouse life span studies used 0.1 ug per mouse subcutaneously in monthly 5 day courses. Human reports from the developer's institute describe 10 mg intramuscular courses of the related extract Epithalamin, not a dose finding study of epitalon. No human pharmacokinetic or dose ranging study has been published.
Routes reported
| # | Route |
|---|---|
| 1 | Subcutaneous injection (as sold) |
| 2 | Intramuscular injection (Russian Epithalamin reports) |
| 3 | Intranasal and oral products exist without absorption data |
Epitalon side effects
Side effects
| # | Reported side effect |
|---|---|
| 1 | No systematic human safety data published |
| 2 | Injection site reactions reported anecdotally |
| 3 | Theoretical concern that telomerase activation could support growth of existing tumors, although mouse studies reported fewer spontaneous tumors |
| 4 | Effects on melatonin rhythm are reported in two human studies and could alter sleep timing |
Interactions
| # | Interaction |
|---|---|
| 1 | No formal human interaction studies exist |
| 2 | Theoretical additive effects with melatonin or sedatives given proposed pineal effects (not tested) |
Contraindications
| # | Contraindication |
|---|---|
| 1 | Active cancer or history of cancer (theoretical telomerase concern, untested in humans) |
| 2 | Pregnancy and breastfeeding (no data) |
| 3 | Competitive athletes subject to WADA testing (prohibited at all times under S0) |
How do people access Epitalon legally?
Typical cost: No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient epitalon on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.
Access options
Conditional
Compounded access under HHS's draft policy (announced October 28, 2026): HHS says it does not intend to take enforcement action when a state-licensed pharmacy or licensed physician compounds single-ingredient epitalon by injection under the skin or into muscle, in intermittent courses on a patient-specific prescription, under strict quality and reporting conditions. The policy is a draft, is not binding, and HHS may revisit it. Blends and stacks are not covered, and state law still applies.
Not available
Not available as an FDA approved product.
Not available
Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.
Access paths are checked against public regulatory records. Products labeled research use only are never listed.
Compare Epitalon
What's actually offered, and what that means for you
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [14] [15] [16]
In October 2026, HHS released a draft policy saying it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds epitalon as a single-ingredient product by subcutaneous or intramuscular injection, in intermittent courses, on a patient-specific prescription, from an FDA-registered manufacturer with a tested certificate of analysis. It is not an FDA approval and does not put epitalon on the 503A bulks list; the policy is not binding, and HHS may revisit it. Blends that mix epitalon with other peptides are not covered, and state rules still apply. [12] [13]
What FDA found
- July 2026: FDA's review found wellness clinics marketing epitalon, some saying they get it from a compounding pharmacy, and websites selling it, but FDA could not identify a pharmacy compounding it. [17]
- January 2026: FDA cited a 503B outsourcing facility's epitalon product for a label missing required statements, in a letter that also cites sterility failures and ineligible bulk substances. [18]
- April 2020: FDA named epitalon among the bulk substances a state-licensed 503A pharmacy compounded outside section 503A. [15]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [14] [19] [20] [21] [22] [23]
What that means for you
- A pharmacy that compounds epitalon relies on HHS's draft policy, which has strict conditions and which HHS can revisit, so it carries some regulatory risk. Compounding it outside those conditions, such as in a blend or by another route, has no federal basis. [13]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [23]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [24]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [25] [26]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [21]
- Insurance rarely covers it, so you usually pay cash.
- For tested athletes, epitalon is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [9]
If you're going ahead anyway
These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [23]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [27] [28] [29]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [16] [29] [30]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [23] [31] [32] [33] [34] [35]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [23]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [27]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [16]
- Pharmacy: Is this made for me on a prescription written in my name? [30]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [16] [29]
- Prescriber: What is the legal basis for a pharmacy to compound epitalon? Is it FDA approved or on the 503A bulks list? [7] [23]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [16]
In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [24]
Frequently asked questions
What is epitalon peptide, and is epithalon the same thing?
Yes, they are the same. Epitalon, epithalon, and epithalone are spellings of one synthetic four amino acid peptide, Ala-Glu-Asp-Gly (AEDG). It was made in St. Petersburg as a defined version of Epithalamin, an extract of bovine (cow) pineal gland, a small hormone gland in the brain, and is marketed for longevity. It is not FDA approved. In July 2026 FDA's drug center recommended against adding it to the 503A bulks list (ingredients pharmacies may use to compound drugs for individual patients) and the advisory committee voted in favor, and in October 2026 HHS released a draft policy under which it does not intend to take enforcement action against licensed pharmacies that compound single-ingredient epitalon under strict conditions. [8] [10] [13]
Is epitalon legal in the United States?
It is not an FDA approved drug, but possessing it is not a crime. It was on the 503A Category 2 list from September 2023 until April 22, 2026, when its nomination was withdrawn. At the July 24, 2026 Pharmacy Compounding Advisory Committee meeting, FDA's drug center (CDER) recommended against adding it to the 503A bulks list and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026 HHS released a draft enforcement discretion policy: HHS says it does not intend to take enforcement action against licensed pharmacies and physicians that compound single-ingredient epitalon by injection under the skin or into muscle, in intermittent courses on a patient-specific prescription, under strict quality and reporting conditions. It is a draft, not an approval or a bulks listing, and HHS may revisit it. Blends and stacks are not covered, and state law still applies. Research chemical products sold for human use are still unapproved drugs. [7] [8] [11] [12] [13]
Epitalon benefits: what does the evidence show?
Most of the claimed benefits come from cell and animal work. In cultured human cells it switched on telomerase and lengthened telomeres. In female mice given monthly courses for life, the longest lived tenth lived longer and fewer spontaneous tumors developed, although average life span did not change. In people, two Russian studies reported higher melatonin output after the peptide, one in elderly people and one in middle-aged people, but their abstracts do not state the design, the sample size, or whether participants were randomized. The 2003 trial often cited for epitalon tested the pineal extract Epithalamin, not epitalon. PeptideAgent grades the evidence human observational: human studies are indexed, but none is a confirmed randomized trial of epitalon, and the grade describes how the evidence was gathered, not whether the peptide works. [1] [2] [3] [4] [5]
Does epitalon actually lengthen telomeres or extend life?
In cultured human cells, yes: epitalon increased telomerase activity and telomere length in a 2003 study and again in a 2025 study across several cell lines. In mice, monthly courses increased the life span of the longest lived 10% and reduced tumors but did not change mean life span. No human study has measured telomere length or life span after epitalon, so the human claim is untested. [1] [2] [6]
How does epitalon work?
The proposed mechanisms come from cell and animal studies. Epitalon increases expression and activity of telomerase, the enzyme that rebuilds the protective ends of chromosomes, and a 2025 study found telomere lengthening in several human cell lines through telomerase or an alternative pathway. A 2025 review also summarizes effects on melatonin synthesis, antioxidant enzymes, and gene expression. Two Russian human studies reported higher melatonin output after the peptide, though their abstracts do not state the study design. The telomere effects have not been measured in people, and no human pharmacokinetic study has been published, so its half-life in people is unknown. [1] [3] [4] [6] [10]
What are the side effects of epitalon?
No systematic human safety study exists. Anecdotal reports mention injection site irritation. The main theoretical concern is that a telomerase activator could help existing cancer cells keep dividing, though treated mice actually developed fewer spontaneous tumors. That question has never been studied in people. [1] [2]
How is epitalon taken?
In mouse studies it was injected subcutaneously in monthly 5 day courses. Russian human reports used intramuscular courses of the related pineal extract Epithalamin. Products sold to people are usually injection vials, with some intranasal and oral versions that have no absorption data. There is no human dose finding study. [2] [5]
How much does epitalon cost?
There is no verified price. HHS's October 2026 draft policy says HHS does not intend to take enforcement action against licensed pharmacies that compound single-ingredient epitalon on a patient-specific prescription under strict conditions, but PeptideAgent has no verified compounded price, and advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity. [11] [13]
Is epitalon banned by WADA?
Yes. Epitalon has no current approval from any government health authority for human use, so it falls under section S0 (non-approved substances) of the WADA Prohibited List and is prohibited at all times. [9]
Epitalon vs thymalin: what is the difference?
Both come from the same St. Petersburg institute. Epitalon is a defined 4 amino acid synthetic peptide modeled on the pineal extract Epithalamin; thymalin is a thymus extract used as an immune modulator. The 2003 human trial that is often cited for epitalon actually tested the extracts Epithalamin and Thymalin in elderly people; its paper describes it as randomized and placebo controlled, but it did not test synthetic epitalon. Neither has an independently replicated randomized trial or FDA approval. [5]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
From the blog
- Epitalon human studies: what the small cohorts actually measured
Most epitalon human data come from one group and used the pineal extract Epithalamin, not synthetic epitalon. What each study measured, the claimed benefits versus the evidence, and side effects.
- RFK Jr.'s peptide policy: what HHS changed for BPC-157 and five other peptides
HHS released a draft policy on October 28, 2026: it will not act against licensed compounding of BPC-157, TB-500, epitalon, KPV, MOTS-c, or semax under strict conditions. It is not FDA approval.
- FDA's briefing opposed listing seven peptides. What the PCAC meeting changes and what it does not
FDA's briefing recommended against listing BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP. HHS later confirmed the committee voted in favor of the first six.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 2003PubMed 12937682, 2003
- [2]Anisimov VN et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology 2003PubMed 14501183, 2003
- [3]Korkushko OV et al. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Adv Gerontol 2007PubMed 17969590, 2007
- [4]Ivko OM et al. AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging. Adv Gerontol 2020PubMed 33280326, 2020
- [5]Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett 2003PubMed 14523363, 2003
- [6]Al-Dulaimi S et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025PubMed 40908429, 2025
- [7]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [8]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [9]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
- [10]Araj SK et al. Overview of Epitalon, highly bioactive pineal tetrapeptide with promising properties. Int J Mol Sci 2025PubMed 40141333, 2025
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, November 1). Epitalon: evidence, legality, and access. https://peptideagent.ai/peptides/epitalon- HTML link
<a href="https://peptideagent.ai/peptides/epitalon">Epitalon: evidence, legality, and access</a>, PeptideAgent, updated November 1, 2026.